Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
Top Cited Papers
- 23 October 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (17) , 1786-1801
- https://doi.org/10.1056/nejmoa0802670
Abstract
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.This publication has 30 references indexed in Scilit:
- The window of therapeutic opportunity in multiple sclerosisZeitschrift für Neurologie, 2005
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001
- Semiparametric Regression for the Mean and Rate Functions of Recurrent EventsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2000
- Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosisPublished by Elsevier ,1999
- Progressive cerebral atrophy in multiple sclerosis A serial MRI studyBrain, 1996
- Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosisThe Lancet, 1994
- Some large‐sample distribution‐free estimators and tests for multivariate partially incomplete data from two populationsStatistics in Medicine, 1992
- A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinantsJournal of Immunological Methods, 1990
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988
- Rating neurologic impairment in multiple sclerosisNeurology, 1983